Telix Quarterly Results and Investor Call / Webcast Notification
Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 September 2023 on Wednesday 18 October 2023.
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
Telix today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise stated.
Telix Half-Year Results 2023 and Investor Call / Webcast Notification
Telix today advises that it will release its financial results for the half-year ended 30 June 2023 on Wednesday 23 August 2023.
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise stated and provided on an unaudited basis.
Telix Quarterly Results and Investor Call / Webcast Notification
Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 June 2023 on Wednesday 19 July 2023 at market close.
Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical
Telix today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is a United Kingdom-based medical device company specialising in the intra-operative detection of targeted radiopharmaceuticals.
Telix Urology Innovation Showcase – June 21, 2023, at The Yale Club, New York City
Telix today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am EDT and via live webcast (10.30pm AEST). The briefing session will provide an opportunity for shareholders to hear from the Company in relation to its recent market disclosures and will focus on:
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
Telix today announces that the first patient has been dosed in a global Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of cancer indications.
Telix AGM 2023
Telix's 2023 AGM was held on Wednesday, 24th May 2023 at The Events Centre in Melbourne, Australia and online.
ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller
Telix today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).